1 – 10 of 16
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Genome-wide investigation of persistence with methotrexate treatment in early rheumatoid arthritis
(
- Contribution to journal › Article
- 2023
-
Mark
Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice : Results from the ARTIS programme
(
- Contribution to journal › Article
- 2022
-
Mark
Complement C4 copy number variation is linked to SSA/Ro and SSB/La autoantibodies in systemic inflammatory autoimmune diseases
(
- Contribution to journal › Article
-
Mark
Genome-wide association study identifies Sjögren's risk loci with functional implications in immune and glandular cells
(
- Contribution to journal › Article
- 2021
-
Mark
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population : A nationwide Swedish cohort study
(
- Contribution to journal › Article
-
Mark
Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden : From infection severity to impact on care provision
(
- Contribution to journal › Article
-
Mark
Genetic and clinical basis for two distinct subtypes of primary Sjögren's syndrome
(
- Contribution to journal › Article
- 2020
-
Mark
Increased risk of multiple myeloma in primary Sjögren's syndrome is limited to individuals with Ro/SSA and La/SSB autoantibodies
(
- Contribution to journal › Letter
-
Mark
Active conventional treatment and three different biological treatments in early rheumatoid arthritis : Phase IV investigator initiated, randomised, observer blinded clinical trial
(
- Contribution to journal › Article
- 2017
-
Mark
Long-term follow-up in primary Sjögren's syndrome reveals differences in clinical presentation between female and male patients
(
- Contribution to journal › Article